Overview

Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%.

Status:
Terminated
Trial end date:
2020-03-24
Target enrollment:
Participant gender:
Summary
Phase III clinical study of non-inferiority, multicenter, double-blind, with comparative group, of parallel groups and randomized. about a ophthalmic topical antibiotic for the treatment of bacterial conjunctivitis. Goal:To compare the efficacy of the ophthalmic solution of pazufloxacin 0.6%, against the ophthalmic solution of gatifloxacin 0.3%, in the treatment of acute bacterial conjunctivitis. Hypothesis:the ophthalmic solution PRO-157 is not inferior in the treatment of bacterial conjunctivitis, compared to the ophthalmic solution of gatifloxacin 0.3%, by means of the clinical remission of the disease. Number of patients: 160 patients, each one will provide an eye for efficacy analysis, divided into 2 groups (80 eyes per group).
Phase:
Phase 3
Details
Lead Sponsor:
Laboratorios Sophia S.A de C.V.
Treatments:
Fluoroquinolones
Gatifloxacin
Ophthalmic Solutions
Pazufloxacin